These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

432 related items for PubMed ID: 8621927

  • 1. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.
    Rivoltini L, Loftus DJ, Barracchini K, Arienti F, Mazzocchi A, Biddison WE, Salgaller ML, Appella E, Parmiani G, Marincola FM.
    J Immunol; 1996 May 15; 156(10):3882-91. PubMed ID: 8621927
    [Abstract] [Full Text] [Related]

  • 2. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella E, Rosenberg SA.
    J Immunol; 1998 Dec 15; 161(12):6985-92. PubMed ID: 9862734
    [Abstract] [Full Text] [Related]

  • 3. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA.
    J Immunol; 1995 Apr 15; 154(8):3961-8. PubMed ID: 7706734
    [Abstract] [Full Text] [Related]

  • 4. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E.
    J Immunol; 1995 Mar 01; 154(5):2257-65. PubMed ID: 7868898
    [Abstract] [Full Text] [Related]

  • 5. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides.
    Salgaller ML, Afshar A, Marincola FM, Rivoltini L, Kawakami Y, Rosenberg SA.
    Cancer Res; 1995 Nov 01; 55(21):4972-9. PubMed ID: 7585538
    [Abstract] [Full Text] [Related]

  • 6. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y, Maruyama K, Tai S, Takikawa M, Ohshita C, Yamamoto A, Yamazaki N, Kiyohara Y, Yamaguchi K.
    Int J Oncol; 2008 Sep 01; 33(3):433-41. PubMed ID: 18695871
    [Abstract] [Full Text] [Related]

  • 7. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
    Skipper JC, Kittlesen DJ, Hendrickson RC, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL.
    J Immunol; 1996 Dec 01; 157(11):5027-33. PubMed ID: 8943411
    [Abstract] [Full Text] [Related]

  • 8. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen.
    van Elsas A, van der Burg SH, van der Minne CE, Borghi M, Mourer JS, Melief CJ, Schrier PI.
    Eur J Immunol; 1996 Aug 01; 26(8):1683-9. PubMed ID: 8765006
    [Abstract] [Full Text] [Related]

  • 9. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
    Bettinotti MP, Kim CJ, Lee KH, Roden M, Cormier JN, Panelli M, Parker KK, Marincola FM.
    J Immunol; 1998 Jul 15; 161(2):877-89. PubMed ID: 9670966
    [Abstract] [Full Text] [Related]

  • 10. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y.
    J Immunol; 1996 Sep 15; 157(6):2539-48. PubMed ID: 8805655
    [Abstract] [Full Text] [Related]

  • 11. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC.
    J Immunol; 1998 Dec 15; 161(12):6970-6. PubMed ID: 9862732
    [Abstract] [Full Text] [Related]

  • 12. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
    Yang S, Linette GP, Longerich S, Roberts BL, Haluska FG.
    Cell Immunol; 2000 Aug 25; 204(1):29-37. PubMed ID: 11006015
    [Abstract] [Full Text] [Related]

  • 13. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.
    Cancer Res; 1997 Feb 15; 57(4):735-41. PubMed ID: 9044853
    [Abstract] [Full Text] [Related]

  • 14. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.
    Fleischhauer K, Tanzarella S, Wallny HJ, Bordignon C, Traversari C.
    J Immunol; 1996 Jul 15; 157(2):787-97. PubMed ID: 8752930
    [Abstract] [Full Text] [Related]

  • 15. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide.
    Valmori D, Gervois N, Rimoldi D, Fonteneau JF, Bonelo A, Liénard D, Rivoltini L, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Dec 15; 161(12):6956-62. PubMed ID: 9862730
    [Abstract] [Full Text] [Related]

  • 16. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: unexpected high level presentation of tyrosinase-HLA-A2 Complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies.
    Michaeli Y, Denkberg G, Sinik K, Lantzy L, Chih-Sheng C, Beauverd C, Ziv T, Romero P, Reiter Y.
    J Immunol; 2009 May 15; 182(10):6328-41. PubMed ID: 19414786
    [Abstract] [Full Text] [Related]

  • 17. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes.
    Maeurer MJ, Chan HW, Karbach J, Salter RD, Knuth A, Lotze MT, Storkus WJ.
    Eur J Immunol; 1996 Nov 15; 26(11):2613-23. PubMed ID: 8921947
    [Abstract] [Full Text] [Related]

  • 18. Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins.
    Kang X, Robbins PF, Fitzgerald EB, Wang R, Rosenberg SA, Kawakami Y.
    Cancer Res; 1997 Jan 15; 57(2):202-5. PubMed ID: 9000554
    [Abstract] [Full Text] [Related]

  • 19. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L.
    Cancer Res; 2006 May 01; 66(9):4943-51. PubMed ID: 16651452
    [Abstract] [Full Text] [Related]

  • 20. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
    Valmori D, Fonteneau JF, Lizana CM, Gervois N, Liénard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P.
    J Immunol; 1998 Feb 15; 160(4):1750-8. PubMed ID: 9469433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.